PharmaPoint: Rheumatoid Arthritis - France Drug Forecast and Market Analysis Event-Driven Update


#157662

135pages

GlobalData

$ 4995

In Stock


PharmaPoint: Rheumatoid Arthritis France Drug Forecast and Market Analysis Event-Driven Update

Summary

GlobalData has released its new Country report, PharmaPoint: Rheumatoid Arthritis France Drug Forecast and Market Analysis Event-Driven Update. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizers Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lillys anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZs SYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt to dislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven once they enter the market.

French physicians included in this report may follow guidelines such as ACR, but also follow their own clinical experience to treat RA patients. In France, about 29% of referrals of patients presenting in any stage come from PCPs; however, other specialists including orthopedic surgeons are high referrers as well. Also, most people seeking treatment are 55 years and older. Within this age group, females outnumber the males by a small margin compared with the younger age groups.

Scope

  • Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in the France including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in France from 2011 to 2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting the France rheumatoid arthritis market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for rheumatoid arthritis
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of rheumatoid arthritis drug performance in France
  • Obtain sales forecast from 2011-2022 in France